Steering anti-cancer drugs away from the TRAIL.
Nagata
S
S
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D017209:Apoptosis; D051017:Apoptosis Regulatory Proteins; D002986:Clinical Trials as Topic; D053222:Fas Ligand Protein; D008099:Liver / Q000187:drug effects*; D008562:Membrane Glycoproteins / Q000494:pharmacology / Q000627:therapeutic use* / Q000633:toxicity*; D018124:Receptors, Tumor Necrosis Factor / Q000378:metabolism; D053221:TNF-Related Apoptosis-Inducing Ligand; D014409:Tumor Necrosis Factor-alpha / Q000494:pharmacology / Q000627:therapeutic use* / Q000633:toxicity*; D019014:fas Receptor / Q000378:metabolism
D000970:Antineoplastic Agents; D051017:Apoptosis Regulatory Proteins; D053222:Fas Ligand Protein; D008562:Membrane Glycoproteins; D018124:Receptors, Tumor Necrosis Factor; D053221:TNF-Related Apoptosis-Inducing Ligand; D014409:Tumor Necrosis Factor-alpha; D019014:fas Receptor